Regulus has built a portfolio of over 250 patents and patent applications world-wide, protecting the company's clinical candidates, therapeutic modulation of microRNAs
with anti-miRs or mimics, and platform technologies.
Humanized" mice with human blood-producing stem cells had changes in the same radiation-responsive microRNAs
as normal mice did.
Thus, the Global MicroRNA
market is witnessing the increasing use of microRNAs
have profound effects on the immune system, acting as 'brakes' that target more than 60 percent of all gene expression.
Select Biosciences has characterized the associations of microRNAs
in various disease classes and presents these detailed associations as “hotspot maps” in this report.
The advanced assay design tool and the LNA(TM) technology is also available through Exiqon's homepage to researchers who want to design their own microRNA
assays for example for microRNAs
discovered through next generation sequencing.
are short, single-stranded, nonprotein-coding RNAs of about 21-24 nucleotides that serve important regulatory functions through repression of protein translation or mRNA degradation (7).
Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs
Structural imaging of that relationship could aid in explaining the still poorly understood mechanisms by which microRNAs
accomplish their cellular tasks.
This data-driven characterization of the microRNAs
and Exosomes landscape is a hands-on document that can be used for competitive benchmarking, business planning, and strategy developmentall the data that have been collected in this industry analysis are presented and they form the basis for the conclusions drawn throughout the market report presented in a format enabling drag-and-drop into business presentations/business plans
a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs
, announced today that it has earned a fourth milestone payment in its collaboration with Biogen (NASDAQ: BIIB) related to progress in the companies' research collaboration to identify microRNAs
as biomarkers for multiple sclerosis ("MS").
There are hundreds of different types of microRNAs